NMRA
HEALTHCARENeumora Therapeutics Inc
$2.33+0.03 (+1.30%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving NMRA Today?
No stock-specific AI insight has been generated for NMRA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.61$3.65
$2.33
Fundamentals
Market Cap$426M
P/E Ratio—
EPS$-1.45
Dividend Yield—
Dividend / Share—
ROE-1.2%
Profit Margin—
Debt / Equity—
Trading
Volume1.7M
Avg Volume (10D)—
Shares Outstanding182.7M
NMRA News
20 articles- Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 7, 2026
- Neumora Therapeutics (NMRA) Is Among the Best Penny Stocks Set to ExplodeYahoo Finance·Apr 12, 2026
- Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare ConferenceYahoo Finance·Apr 6, 2026
- Neumora Therapeutics, Inc. Common Stock Q4 2025 Earnings Call SummaryMoby·Mar 31, 2026
- Neumora Therapeutics Inc (NMRA) Q4 2025 Earnings Call Highlights: Strong Financial Position ...Yahoo Finance·Mar 31, 2026
- Neumora Therapeutics Q4 Earnings Call HighlightsMarketbeat·Mar 30, 2026
- Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 30, 2026
- Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026Yahoo Finance·Mar 16, 2026
- Neumora Therapeutics (NMRA) Positioned to Capitalize on Blockbuster OpportunityYahoo Finance·Mar 10, 2026
- Neumora Therapeutics Inc (NMRA) Sheds More Light on Phase 1b Study of NMRA-511Yahoo Finance·Mar 4, 2026
- Neumora Therapeutics Highlights NMRA-511 AD Agitation Signal, Maps Higher-Dose Plan for 2026Marketbeat·Feb 14, 2026
- 3 Promising Penny Stocks With Market Caps Up To $400MYahoo Finance·Feb 9, 2026
- Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026Yahoo Finance·Feb 4, 2026
- How Eli Lilly's Plan To Buy Ventyx For $1.2 Billion Could Benefit Neumora, NeurocrineYahoo Finance·Jan 8, 2026
- 3 Penny Stocks With Market Caps Under $700MYahoo Finance·Jan 8, 2026
- Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming MilestonesYahoo Finance·Jan 5, 2026
- Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease AgitationYahoo Finance·Jan 5, 2026
- RBC Sees Upside Potential in Neumora Therapeutics (NMRA)Yahoo Finance·Jan 3, 2026
- Promising Penny Stocks To Watch In December 2025Yahoo Finance·Dec 2, 2025
- Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdateYahoo Finance·Nov 6, 2025
All 20 articles loaded
Price Data
Open$2.32
Previous Close$2.30
Day High$2.42
Day Low$2.27
52 Week High$3.65
52 Week Low$0.61
52-Week Range
$0.61$3.65
$2.33
Fundamentals
Market Cap$426M
P/E Ratio—
EPS$-1.45
Dividend Yield—
Dividend / Share—
ROE-1.2%
Profit Margin—
Debt / Equity—
Trading
Volume1.7M
Avg Volume (10D)—
Shares Outstanding182.7M
About Neumora Therapeutics Inc
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company is headquartered in Watertown, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—